Bank of New York Mellon’s Avalo Therapeutics AVTX Stock Holding History

Bank of New York Mellon’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Buy	+102,653	New	+$1.62M	﹤0.01%	2980
2022 Q3	–	Sell	-17	Closed	-$24K	–	4555
2022 Q2	$24K	Sell	17 -39	-70%	-$52.2K	﹤0.01%	4474
2022 Q1	$117K	Hold	56	–	–	﹤0.01%	4377
2021 Q4	$274K	Buy	56 +1	+2%	+$6K	﹤0.01%	4136
2021 Q3	$345K	Buy	55 +4	+8%	+$32.4K	﹤0.01%	3981
2021 Q2	$480K	Buy	51 +6	+13%	+$50.3K	﹤0.01%	3792
2021 Q1	$389K	Buy	45 +5	+13%	+$47.2K	﹤0.01%	3816
2020 Q4	$301K	Buy	40 +13	+48%	+$90.3K	﹤0.01%	3829
2020 Q3	$180K	Buy	27 +1	+4%	+$7.52K	﹤0.01%	3868
2020 Q2	$196K	Buy	26 +6	+30%	+$43.6K	﹤0.01%	3801
2020 Q1	$144K	Buy	20 +1	+5%	+$10.6K	﹤0.01%	3813
2019 Q4	$301K	Hold	19	–	–	﹤0.01%	3803
2019 Q3	$184K	Sell	19 -1	-5%	-$11.2K	﹤0.01%	3922
2019 Q2	$312K	Buy	20 +15	+300%	+$227K	﹤0.01%	3795
2019 Q1	$85K	Sell	5 -1	-17%	-$15K	﹤0.01%	4029
2018 Q4	$53K	Buy	6 +1	+20%	+$11.1K	﹤0.01%	4051
2018 Q3	$68K	Hold	5	–	–	﹤0.01%	4091
2018 Q2	$63K	Hold	5	–	–	﹤0.01%	4060
2018 Q1	$64K	Buy	+5	New	+$56.3K	﹤0.01%	4132
2017 Q3	–	Sell	-9	Closed	-$14K	–	4268
2017 Q2	$14K	Buy	+9	New	+$14.7K	﹤0.01%	4251

Other funds holding AVTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EHI

Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon's AVTX Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 102,653 shares worth $1.9M. The stake represents ﹤0.01% of the portfolio and ranks #2980 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in AVTX as recently as Q2 2022.

Bank of New York Mellon first reported a position in AVTX in Q2 2017 and has held it in 20 quarters since. 30 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Bank of New York Mellon held 102,653 shares of Avalo Therapeutics worth $1.9M as of Q2 2026.
Avalo Therapeutics was a new Bank of New York Mellon position in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2980 holding.
Bank of New York Mellon first reported a position in Avalo Therapeutics in Q2 2017 and has held it in 20 quarters since.
30 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.